section name header

Pronunciation

tess-TOSS-te-rone en-AN-thate

Classifications

Therapeutic Classification: hormones

Pharmacologic Classification: androgens

Indications

BEERS REMS


Unlabeled Use:
  • Masculinizing hormone therapy for transgender men (female-to-male)

Action

  • Responsible for the normal growth and development of male sex organs.
  • Maintenance of male secondary sex characteristics:
    • Growth and maturation of the prostate, seminal vesicles, penis, scrotum;
    • Development of male hair distribution;
    • Vocal cord thickening;
    • Alterations in body musculature and fat distribution.
Therapeutic effects:
  • Correction of hormone deficiency in male hypogonadism:
    • Initiation of male puberty.
  • Suppression of tumor growth in some forms of breast cancer.

Pharmacokinetics

Absorption: Well absorbed following IM and SUBQ administration; absorbed slowly.

Distribution: Unknown.

Protein Binding: 98%.

Metabolism/Excretion: Metabolized by the liver; 90% eliminated in urine as metabolites.

Half-Life: IM: 10–100 min; SUBQ: Unknown.

Time/Action Profile

(androgenic effects)
ROUTEONSETPEAKDURATION
IMunknownunknown2–4 wk
SUBQunknownunknownunknown



Response is highly variable among individuals; may take mo.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: edema, DEEP VEIN THROMBOSIS, blood pressure, MI

Derm: male pattern baldness

EENT: deepening of voice

Endo:

women

hirsutism,

men

gynecomastia

F and E: hypercalcemia, hyperkalemia, hyperphosphatemia

GI: HEPATOTOXICITY, nausea, vomiting

GU:

women

change in libido, clitoral enlargement, menstrual irregularities,

men

erectile dysfunction, priapism, sperm count, prostatic enlargement

Hemat: hematocrit

Local: pain at injection site

Metab: hypercholesterolemia

Neuro: depression, STROKE, SUICIDAL THOUGHTS/BEHAVIOR

Resp: sleep apnea

Interactions

Drug-drug:

Route/Dosage

Male Hypogonadism (Replacement Therapy)

Delayed Male Puberty

Palliative Management of Breast Cancer (in postmenopausal women)

Masculinizing Hormone Therapy for Transgender Men (Female-to-Male) (off-label)

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Delatestryl, Xyosted

Contr. Subst. Schedule

Schedule III (C-III)